Pony AI (NASDAQ:PONY) vs. Simulations Plus (NASDAQ:SLP) Head to Head Review

Simulations Plus (NASDAQ:SLP) and Pony AI (NASDAQ:PONY) are both computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Simulations Plus and Pony AI”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$70.01 million	9.45	$9.95 million	$0.40	82.35
Pony AI	$84.33 million	55.08	N/A	N/A	N/A

Simulations Plus has higher earnings, but lower revenue than Pony AI.

Profitability

This table compares Simulations Plus and Pony AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Simulations Plus	10.97%	6.84%	6.34%
Pony AI	N/A	N/A	N/A

Institutional & Insider Ownership

78.1% of Simulations Plus shares are owned by institutional investors. 19.4% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Simulations Plus and Pony AI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	0	1	5	1	3.00
Pony AI	0	0	3	0	3.00

Simulations Plus currently has a consensus target price of $49.00, suggesting a potential upside of 48.76%. Pony AI has a consensus target price of $19.20, suggesting a potential upside of 44.25%. Given Simulations Plus’ higher possible upside, equities analysts clearly believe Simulations Plus is more favorable than Pony AI.

Summary

Simulations Plus beats Pony AI on 8 of the 10 factors compared between the two stocks.

About Simulations Plus

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

About Pony AI

Pony AI Inc., through its subsidiaries, engages in the autonomous mobility principally in the People’s Republic of China and the United States. The company provides robotruck services, such as transportation services to the logistics platforms. Pony AI Inc. is based in Guangzhou, the People’s Republic of China.